Doctors say blood-clot drug race too close to call

CHICAGO, Nov 15 (Reuters) - A half dozen experimental stroke-prevention drugs, and one already on the market, are racing for their share of a market that could be worth $15 billion a year. But doctors say it is still too early to predict how they will stack up in the marketplace.